Lv6
1630 积分 2024-02-08 加入
Bispecific T cell engager therapy for refractory rheumatoid arthritis
2天前
已完结
BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy
2天前
已完结
One-year remission of therapy-resistant SLE after a single course with the bispecific CD3: BCMA antibody teclistamab, but induction of a non-infectious Crohn’s-like inflammatory bowel disease
2天前
已完结
Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus
2天前
已完结
Phase 1/2 Trial of Anti-CD7 Allogeneic WU-CART-007 in patients with Relapsed/Refractory T-cell Malignancies
4天前
已完结
Allogeneic “Off-the-Shelf” CAR T Cells: Challenges and Advances
5天前
已完结
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
5天前
已完结
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial
10天前
已完结
BAricitinib in patients with SystemIC Sclerosis (BASICS): a prospective, open-label, randomised trial
10天前
已完结
Systemic sclerosis
10天前
已完结
皖公网安备34019202002308
